A recent study led in Italy was organized to investigate the question whether autologous hematopoietic stem cell transplantation (aHSCT) can actually induce durable multiple sclerosis (MS) disease remission in patients with MS by analyzing long-term outcomes post-transplant in a large cohort of MS patients. The Italian-based researchers discovered that of the 210 MS patients actually receiving the aHSCT procedure, that is a stem cell (regenerative) procedure with cells from their own blood, nearly 70% of the total group experienced no degradation in their disability ten years after. This study suggests that this form of regenerative therapy may introduce longer-term benefits for at least some patients with challenging MS cases.
What is MS?
A neurological disorder triggered by a misguided immune system that attacks the body’s own myelin—that is the protective sheath surrounding nerve fibers located in the spine and brain. Symptoms range from muscle weakness and numbness to challenges with balance, coordination and even walking. The MS Society suggests that approximately 85% of those with MS first have a form associated with relapsing-remitting but most ultimately and unfortu...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).